The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
This product will be manufactured at Lupin’s Nagpur facility in India
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
The company uses iPS cells to develop treatments for diseases relating to the kidney
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated
